Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation development and cGMP manufacture of its own psilocybin. Interim results from the PsiGAD trial remain internally confidential to maintain blinding and integrity of the trial, however, a report from the independent data safety monitoring board (DSMB) on the interim results will be released soon, when available.
Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use
Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation
Related Posts
Ancora Issues Letter To Fellow Shareholders Of The Walt Disney Company Regarding The Value Of Adding An Investor Representative To The Board
Fellow Shareholders,Ancora is a shareholder of Disney because its brand, entertainment assets and media holdings can underpin sustained value creation for decades to come. We believe Disney is saying the right things
Novo Integrated Sciences Announces Receipt From Nasdaq Stock Market That Co Is Not In Compliance With Nasdaq’s Continued Listing Requirements
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), today reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock